This is a summary of the European public assessment report (EPAR) for Hirobriz Breezhaler. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Hirobriz Breezhaler. For practical information about using Hirobriz Breezhaler, patients should read the package leaflet or contact their doctor or pharmacist.
Therapeutic Indication
### Therapeutic indication Hirobriz Breezhaler is indicated for maintenance bronchodilator treatment of airflow obstruction in adult patients with chronic obstructive pulmonary disease.
Therapeutic Area (MeSH)
ATC Code
R03AC18
ATC Item
indacaterol
Pharmacotherapeutic Group
Drugs for obstructive airway diseases
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| indacaterol maleate | N/A | 茚达特罗 |
EMA Name
Hirobriz Breezhaler
Medicine Name
Hirobriz Breezhaler
Aliases
N/ANo risk management plan link.
